Simplex Trading
VRDN icon

Simplex Trading’s Viridian Therapeutics VRDN Stock Holding History

Simplex Trading’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Buy
12,700
+10,100
+388% +$300K ﹤0.01% 4040
2025
Q4 		$80.9K Sell
2,600
-4,300
-62% -$118K ﹤0.01% 5203
2025
Q3 		$148K Sell
6,900
-12,100
-64% -$218K ﹤0.01% 5295
2025
Q2 		$265K Sell
19,000
-5,400
-22% -$73.3K ﹤0.01% 4211
2025
Q1 		$328K Buy
24,400
+9,600
+65% +$164K ﹤0.01% 3848
2024
Q4 		$283K Buy
14,800
+8,400
+131% +$183K ﹤0.01% 4128
2024
Q3 		$145K Sell
6,400
-46,800
-88% -$765K ﹤0.01% 4849
2024
Q2 		$692K Buy
53,200
+52,300
+5,811% +$724K ﹤0.01% 3311
2024
Q1 		$15K Sell
900
-500
-36% -$9.69K ﹤0.01% 7345
2023
Q4 		$30K Buy
1,400
+400
+40% +$6.31K ﹤0.01% 6566
2023
Q3 		$15K Sell
1,000
-2,900
-74% -$55.3K ﹤0.01% 6901
2023
Q2 		$92K Buy
3,900
+3,300
+550% +$84.6K ﹤0.01% 5183
2023
Q1 		$15K Buy
600
+300
+100% +$9.62K ﹤0.01% 7209
2022
Q4 		$8K Sell
300
-21,000
-99% -$484K ﹤0.01% 7761
2022
Q3 		$436K Buy
+21,300
New +$383K ﹤0.01% 3625
2022
Q2 		– Sell
-10,800
Closed -$199K – 11205
2022
Q1 		$199K Buy
+10,800
New +$208K ﹤0.01% 5157

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Simplex Trading's VRDN Position: Q4 2025 in Review

Simplex Trading sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 2,756 shares — an estimated $75.6K sold.

Simplex Trading first reported a position in VRDN in Q2 2022 and held it in 10 quarters. The position peaked at $556K in Q2 2023. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Simplex Trading reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 2,756 Viridian Therapeutics shares in Q4 2025, an estimated $75.6K.
  • Simplex Trading first reported a position in Viridian Therapeutics in Q2 2022 and held it in 10 quarters.
  • Simplex Trading's Viridian Therapeutics position peaked at $556K in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.